GLA
AMLX icon

Great Lakes Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Great Lakes Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Buy
12,807
+2,427
+23% +$37.5K ﹤0.01% 765
2026
Q1 		$144K Buy
+10,380
New +$146K ﹤0.01% 778

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Great Lakes Advisors's AMLX Position: Q2 2026 in Review

Great Lakes Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 23% in Q2 2026, buying an estimated $37.5K and bringing the position to 12,807 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #765.

Great Lakes Advisors first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Great Lakes Advisors held 12,807 shares of Amylyx Pharmaceuticals worth $230K as of Q2 2026.
  • Great Lakes Advisors bought 2,427 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $37.5K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #765 holding.
  • Great Lakes Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.